+

WO2003016476A3 - Gene expression profiles in glomerular diseases - Google Patents

Gene expression profiles in glomerular diseases Download PDF

Info

Publication number
WO2003016476A3
WO2003016476A3 PCT/US2002/025766 US0225766W WO03016476A3 WO 2003016476 A3 WO2003016476 A3 WO 2003016476A3 US 0225766 W US0225766 W US 0225766W WO 03016476 A3 WO03016476 A3 WO 03016476A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene expression
glomerular diseases
expression profiles
pbl
glomerular
Prior art date
Application number
PCT/US2002/025766
Other languages
French (fr)
Other versions
WO2003016476A2 (en
Inventor
William E Munger
Ronald Falk
Hongwei Sun
Hitoshi Sasai
Iwao Waga
Jun Yamamoto
Original Assignee
Gene Logic Inc
Univ North Carolina
Japan Tobacco Inc
William E Munger
Ronald Falk
Hongwei Sun
Hitoshi Sasai
Iwao Waga
Jun Yamamoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gene Logic Inc, Univ North Carolina, Japan Tobacco Inc, William E Munger, Ronald Falk, Hongwei Sun, Hitoshi Sasai, Iwao Waga, Jun Yamamoto filed Critical Gene Logic Inc
Priority to AU2002324701A priority Critical patent/AU2002324701A1/en
Publication of WO2003016476A2 publication Critical patent/WO2003016476A2/en
Publication of WO2003016476A3 publication Critical patent/WO2003016476A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention is based on the elucidation of the global changes in gene expression in PBL of the patients with glomerular diseases exhibiting different types of clinical and pathological features of glomerular nephropathy as compared to normal PBL as well as the identification of individual genes that are differently expressed in PBL of patients with glomerular diseases.
PCT/US2002/025766 2001-08-14 2002-08-14 Gene expression profiles in glomerular diseases WO2003016476A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002324701A AU2002324701A1 (en) 2001-08-14 2002-08-14 Gene expression profiles in glomerular diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31183701P 2001-08-14 2001-08-14
US60/311,837 2001-08-14

Publications (2)

Publication Number Publication Date
WO2003016476A2 WO2003016476A2 (en) 2003-02-27
WO2003016476A3 true WO2003016476A3 (en) 2003-05-08

Family

ID=23208719

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/025766 WO2003016476A2 (en) 2001-08-14 2002-08-14 Gene expression profiles in glomerular diseases

Country Status (2)

Country Link
AU (1) AU2002324701A1 (en)
WO (1) WO2003016476A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7253148B2 (en) 2003-03-07 2007-08-07 The Research Foundation Of State University Of New York Human gene with immunoregulatory and anti-proliferative properties
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
US7608395B2 (en) * 2005-09-15 2009-10-27 Baylor Research Institute Systemic lupus erythematosus diagnostic assay

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6114123A (en) * 1999-06-14 2000-09-05 Incyte Pharmaceuticals, Inc. Lipocalin family protein
US6268342B1 (en) * 1996-08-30 2001-07-31 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268342B1 (en) * 1996-08-30 2001-07-31 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
US6114123A (en) * 1999-06-14 2000-09-05 Incyte Pharmaceuticals, Inc. Lipocalin family protein

Also Published As

Publication number Publication date
AU2002324701A1 (en) 2003-03-03
WO2003016476A2 (en) 2003-02-27

Similar Documents

Publication Publication Date Title
WO2004065583A3 (en) Gene expression markers for breast cancer prognosis
WO2006050475A3 (en) Identification of dysregulated genes in patients with neurological diseases
WO2002074992A3 (en) Phosphodiesterase 4d genes related to human stroke
EP1412371A4 (en) IN VIVO MANUFACTURE OF SMALL INTERFERING RNAs THAT TRANSFER TO GENES
WO2004028339A3 (en) Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues
WO2008057457A3 (en) Antagonists of pcsk9
WO2008133647A3 (en) Antagonists of pcsk9
EP1509226A4 (en) SMALL INHIBITORY MOLECULES OF HER2 GENE EXPRESSION
ATE450622T1 (en) GENES AND PROTEINS FOR PREVENTION, PREDICTION, PROGNOSIS AND THERAPY OF CARDIOVASCULAR DISEASE
WO2002012440A3 (en) Identifying drugs for and diagnosis of benign prostatic hyperplasia using gene expression profiles
WO2003089622A3 (en) Novel genes, compositions, and methods for modulating the unfolded protein response
WO2005001039A3 (en) Ribozyme-regulated small inhibitory rna (sirna) production and methods of use thereof
WO2004063340A3 (en) Methods and compositions for treating cardiovascular disease using 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061,17662,1468,12282, 6350, 9035,1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123,12788,17729, 65552,1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612, 10671, 261, 44570, 4
WO2003016476A3 (en) Gene expression profiles in glomerular diseases
WO2003027633A3 (en) Identifying drugs for and diagnosis of benign prostatic hyperplasia using gene expression profiles
WO2005022164A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 8 (klk8)
WO2007115068A8 (en) Genetic variants in the indoleamine 2,3-dioxygenase gene
WO2003050504A3 (en) Methods and compositions to treat cardiovascular disease usin g 1419, 58765 and 2201
WO2003026566A3 (en) Atlastin
WO2003050303A3 (en) Biallelic markers of d-amino acid oxidase and uses thereof
WO2004053117A3 (en) Serine protease
WO2004056983A3 (en) Metalloprotease proteins
WO2005052180A3 (en) Ntrk1 genetic markers associated with progression of alzheimer’s disease
WO2005042706A3 (en) Ephx2 genetic markers associated with galantamine response
WO2005075662A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 2 (klk2)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载